Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected - 21/09/21
, Samuele Sabbatini b, 1, Sabrina Bastianelli a, Sara Pierucci a, Chiara Busti a, Claudia Monari b, Barbara Luciani Pasqua c, Filippo Dragoni d, Elisabetta Schiaroli a, Maurizio Zazzi d, Daniela Francisci a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | B.1.1.7 and P.1 are less efficiently neutralized by wild-type convalescent serums. |
• | Vaccine-elicited serums maintain the neutralizing potency for B.1.1.7. |
• | Vaccine-elicited serums have a reduced neutralizing activity against P.1. |
• | P.1 convalescent patients are less protected against other variants. |
Abstract |
Objectives |
The emergence of new variants of concern (VOCs) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) around the world significantly complicated the exit from Coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to evaluate the serum neutralizing activity of three cohorts.
Methods |
BNT162b2-elicited serum (N = 103), candidates as hyper-immune plasma donors (N = 90) and patients infected with the SARS-CoV-2 P1 variant (N = 22) were enrolled. Three strains of SARS-CoV-2 have been tested: 20A.EU1, B.1.1.7 (alpha) and P.1 (gamma). Neutralizing antibodies (NT-Abs) titers against SARS-CoV-2 were evaluated.
Results |
B.1.1.7 and P.1 are less efficiently neutralized by convalescent wild-type infected serums if compared to 20A.EU1 strain (mean titer 1.6 and 6.7-fold lower respectively). BNT162b2 vaccine-elicited human sera show an equivalent neutralization potency on the B.1.1.7 but it is significantly lower for the P.1 variant (mean titer 3.3-fold lower). Convalescent P.1 patients are less protected from other SARS-CoV-2 strains with an important reduction of neutralizing antibodies against 20A.EU1 and B.1.1.7, about 12.2 and 10.9-fold, respectively.
Conclusions |
BNT162b2 vaccine confers immunity against all the tested VOCs, while previous SARS-CoV-2 infection may be less protective.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, SARS-CoV-2, Vaccine, Variant, Antibodies, Neutralizing
Plan
| ORCiD Anna Gidari 0000-0002-6556-6553 Samuele Sabbatini 0000-0001-8334-8325 Claudia Monari 0000-0002-5027-9367 Filippo Dragoni 0000-0002-8148-9914 Elisabetta Schiaroli 0000-0002-3216-4144 Maurizio Zazzi 0000-0002-0344-6281 Daniela Francisci 0000-0001-8752-8278 |
Vol 83 - N° 4
P. 467-472 - octobre 2021 Retour au numéro
Article précédent
- SARS-CoV-2 viral load at presentation to hospital is independently associated with the risk of death
- Alex R Tanner, Hang Phan, Nathan J Brendish, Florina Borca, Kate R Beard, Stephen Poole, Tristan W Clark
- Epidemiological data and genome sequencing reveals that nosocomial transmission of SARS-CoV-2 is underestimated and mostly mediated by a small number of highly infectious individuals
- Sheila F Lumley, Bede Constantinides, Nicholas Sanderson, Gillian Rodger, Teresa L Street, Jeremy Swann, Kevin K Chau, Denise O'Donnell, Fiona Warren, Sarah Hoosdally, OUH Microbiology laboratory, OUH Infection Prevention and Control team, Anne-Marie O'Donnell, Timothy M Walker, Nicole E Stoesser, Lisa Butcher, Tim EA Peto, Derrick W Crook, Katie Jeffery, Philippa C Matthews, David W Eyre
Bienvenue sur EM-consulte, la référence des professionnels de santé.